{
    "clinical_study": {
        "@rank": "122650", 
        "acronym": "CCA", 
        "arm_group": [
            {
                "arm_group_label": "Part 1", 
                "arm_group_type": "Experimental", 
                "description": "single administration : candesartan cilexetil 32mg, qd, 10days(oral).\ncombination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
            }, 
            {
                "arm_group_label": "Part 2", 
                "arm_group_type": "Experimental", 
                "description": "single administration : amlodipine 10mg, qd, 10days(oral).\ncombination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designated to evaluate the pharmacokinetic interactions of candesartan\n      cilexetil and amlodipine besylate in healthy male volunteers."
        }, 
        "brief_title": "Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male volunteers in the age between 20 and 55 years old(inclusive)\n\n          -  Body mass index (BMI) in the range of 18.5 to 27 kg/m2(inclusive)\n\n          -  Available for the entire study period\n\n          -  Understand the requirements of the study and voluntarily consent to participate in\n             the study\n\n        Exclusion Criteria:\n\n          -  Subjects with a history of gastrointestinal diseases which might significantly change\n             ADME of medicines\n\n          -  Systolic blood pressure outside the range of 100 to 150 mmHg or diastolic blood\n             pressure outside the range of 60 to 1000 mmHg for male subjects. when screening\n             period\n\n          -  Subject with symptoms of acute disease within 14days prior to study medication dosing\n\n          -  Subjects with a history of clinically significant allergies\n\n          -  Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase\n             deficiency or glucose-galactose malabsorption\n\n          -  Subjects whose clinical laboratory test values are outside the accepted normal\n             range(Especially,AST or ALT >1.5 times to normal range or total bilirubin > 1.5times\n             to normal range)\n\n          -  History of drug abuse\n\n          -  History of caffeine, alcohol, smoking abuse\n\n               -  caffeine(coffee,tea,coke) or grapefruit juice > 4cups/day\n\n               -  smoking > 20 cigarettes/day\n\n               -  alcohol > 140g/week\n\n          -  Positive test results for HBs Ab, HCV Ab, Syphilis regain test\n\n          -  Participation in any clinical investigation within 30days prior to study medication\n             dosing\n\n          -  Subjects with whole blood donation within 60days, component blood donation within\n             30days and blood transfusion within 30days prior to study medication dosing\n\n          -  Subjects considered as unsuitable based on medical judgement by investigators"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845272", 
            "org_study_id": "CJ_CCA_101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part 1", 
                    "Part 2"
                ], 
                "description": "Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover", 
                "intervention_name": "candesartan cilexetil 32mg, amlodipine 10mg", 
                "intervention_type": "Drug", 
                "other_name": "atacand 32mg, norvasc 10mg"
            }, 
            {
                "arm_group_label": [
                    "Part 1", 
                    "Part 2"
                ], 
                "description": "Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover", 
                "intervention_name": "candesartan cilexetil 32mg, amlodipine 10mg", 
                "intervention_type": "Drug", 
                "other_name": "atacand 32mg, norvasc 10mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Candesartan cilexetil", 
                "Candesartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 30, 2013", 
        "number_of_arms": "2", 
        "official_title": "Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate in Healthy Male Volunteers.", 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Jae-wook Ko, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Assessment of the drug-drug interactions of candesartan and amlodipine", 
            "safety_issue": "No", 
            "time_frame": "10 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845272"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}